Novel Tubulin Targeting Anti-Cancer Drug
The use of microtubule-targeting agents has significantly increased response and survival among cancer patients including solid tumors and hematological malignancies. However, they are effective until patients develop drug resistance or serious side-effects.
STK405759 is a novel microtubule targeting agent with potent and selective cytotoxic activity in preclinical models of multiple myeloma that can overcome MDR1 multi-drug resistance. In our research the aim is to identify a molecule derived from STK405759 with improved chemical properties and a broader therapeutic window for treatment of multiple myeloma and other malignancies. By combining in silico screening with chemical optimization and comprehensive biological models we have identified novel molecules that are currently being validated.
Team Members : Gabriela Rozic, Irit Shapira, Anael Hayun, Igor Koman, Merav Leiba